A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Advanced Solid Cancer Clinical Trial

Official title:
An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Patients With Advanced Solid Tumors

Status Recruiting

Clinical Trial Summary

The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with advanced solid cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Solid Cancer

Clinical Trial Details

NCT number	NCT04877717
Study type	Interventional
Source	Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact	Chunlei Jin, Ph.D.
Phone	+86-021-23511999
Email	chunlei.jin@hengrui.com
Status	Recruiting
Phase	Phase 1
Start date	July 1, 2021
Completion date	January 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01416623` - A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies	Phase 1
Recruiting	`NCT03618043` - Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer	Phase 1
Recruiting	`NCT03917043` - APG-2449 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT03884517` - Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer	Phase 1
Recruiting	`NCT03791112` - A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor	Phase 1
Recruiting	`NCT05770310` - A Phase I Study Of JS015 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05947474` - ORB-011 In Patients With Advanced Solid Tumors	Phase 1